RecruitingPhase 1

A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

China64 participantsStarted 2025-09-18

Plain-language summary

he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups

Who can participate

Age range18 Years – 45 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy adult subjects
✓. Signed informed consent

Exclusion criteria

✕. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects.
✕. Prior use of drug targeting TNF-like cytokine 1A
✕. history of malignant tumor
✕. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)

What they're measuring

Adverse events

Timeframe: 16 weeks

Trial details

NCT IDNCT07199270

SponsorGenrix (Shanghai) Biopharmaceutical Co., Ltd.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-09-18

Contact for this trial

Nian

021-50805989-08324 nianhanli@genrixbio.com

View on ClinicalTrials.gov More Health Adult Subjects trials